在癌症中对L-asparaginase耐药性的机制性见解
Longfei Deng1, Jingjie Zhou1, Yujie Liu1
1Cancer Center, Medical Research Institute, Southwest University, Chongqing 400715, China; Engineering Research Center for Cancer Biomedical and Translational Medicine, Southwest University, Chongqing 400715, China; Jinfeng Laboratory, Chongqing 401329, China.
Cellular signalling
|December 12, 2025
概括
L-阿斯巴拉金酶 (ASNase) 通过饥饿L-阿斯巴拉金 (Asn) 的癌细胞来治疗急性淋巴细胞白血病. 然而,癌细胞会产生抗性,从而限制ASNase.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚斯巴拉酶 (ASNase) 是急性淋巴细胞白血病 (ALL) 的关键化疗剂,通过耗尽L-亚斯巴拉 (Asn) 来诱导癌细胞死亡.
- 尽管它取得了成功,但对ASNase疗法的耐药性是一个重大的临床挑战,导致疾病复发并限制其在固体瘤中的应用.
- 在ASNase耐药性背后的分子机制仍然不完全理解,需要进行全面的审查.
研究的目的:
- 提供ASNase在癌症治疗中的当前临床应用的概述.
- 总结和讨论各种人类癌症中ASNase耐药性的最新分子机制.
- 提出一个复杂的监管网络,有助于ASNase耐药性.
主要方法:
- 文献评论专注于过去十年或更长时间内发表的研究.
- 在不同癌症类型中分析ASNase抵抗的分子机制.
- 综合发现,提出一个监管网络,支持抵抗.
主要成果:
- 通过利用某些癌细胞对非必需氨基酸的需求,ASNase有效地治疗ALL.
- 对ASNase耐药性的出现是一个常见的现象,影响治疗疗效和预后.
- 确定了多样化和复杂的分子机制,有助于在不同癌症中促进ASNase耐药性.
结论:
- 了解ASNase抵抗机制对于克服治疗局限性和改善患者结果至关重要.
- 对ASNase耐药性监管网络的进一步研究可能会揭示新的治疗策略.
- 扩大ASNase的应用到固体瘤需要解决固有的抵抗机制.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Ligand Binding and Linkage
5.4K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.4K
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Allosteric Proteins-ATCase
6.4K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.4K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


